Literature DB >> 12669461

Toward third-generation aptamers: Spiegelmers and their therapeutic prospects.

Axel Vater1, Sven Klussmann.   

Abstract

Single-stranded mirror-image oligonucleotides, which are highly resistant to nuclease degradation and are capable of tightly and specifically binding to protein targets to inhibit their function, have been developed as potential therapeutic agents. The scientific discoveries that led to the development of the Spiegelmer technology are described in this review, along with recent preclinical developments of the first therapeutic Spiegelmers.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12669461

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN： 1367-6733


  32 in total

1.  Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX.

Authors:  Axel Vater; Florian Jarosch; Klaus Buchner; Sven Klussmann
Journal:  Nucleic Acids Res       Date:  2003-11-01       Impact factor: 16.971

Review 2.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

Review 3.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

Review 4.  Tumor-targeted drug delivery with aptamers.

Authors:  Y Zhang; H Hong; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

Review 5.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

6.  Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene.

Authors:  Jeffrey S Mogil; Frank Miermeister; Frank Seifert; Kate Strasburg; Katharina Zimmermann; Heiko Reinold; Jean-Sebastien Austin; Nadia Bernardini; Elissa J Chesler; Heiko A Hofmann; Christian Hordo; Karl Messlinger; Kumar V S Nemmani; Andrew L Rankin; Jennifer Ritchie; Angela Siegling; Shad B Smith; Susana Sotocinal; Axel Vater; Sonya G Lehto; Sven Klussmann; Remi Quirion; Martin Michaelis; Marshall Devor; Peter W Reeh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

7.  The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.

Authors:  Julia Hoellenriegel; Dirk Zboralski; Christian Maasch; Nathalie Y Rosin; William G Wierda; Michael J Keating; Anna Kruschinski; Jan A Burger
Journal:  Blood       Date:  2013-11-25       Impact factor: 22.113

8.  Strategies for the discovery of therapeutic aptamers.

Authors:  Xianbin Yang; Na Li; David G Gorenstein
Journal:  Expert Opin Drug Discov       Date:  2011-01       Impact factor: 6.098

9.  Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer.

Authors:  Steffen Helmling; Christian Maasch; Dirk Eulberg; Klaus Buchner; Werner Schröder; Christian Lange; Stefan Vonhoff; Britta Wlotzka; Matthias H Tschöp; Stefan Rosewicz; Sven Klussmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

10.  Biostable aptamers with antagonistic properties to the neuropeptide nociceptin/orphanin FQ.

Authors:  Dirk Faulhammer; Bernd Eschgfäller; Sandra Stark; Petra Burgstaller; Werner Englberger; Jeannette Erfurth; Frank Kleinjung; Johanna Rupp; Sebastian Dan Vulcu; Werner Schröder; Stefan Vonhoff; Hermann Nawrath; Clemens Gillen; Sven Klussmann
Journal:  RNA       Date:  2004-03       Impact factor: 4.942
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.